Paper Details

  1. Home
  2. Paper Details

Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.

Author: KjellströmUlrika, Lövestam-AdrianMonica, SchroederMarion

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized clinical trial compared two aflibercept treatment regimens for age-related macular degeneration (nAMD) over 18 months. Both treatment arms received a similar number of injections at comparable intervals. Electrophysiological evaluation showed no signs of toxicity concerning cone function, but the combined and isolated rod response declined, possibly reflecting either toxic effects of the drug to rods or the natural course of the disease.
Paper Details　
Original Abstract of the Article :
PURPOSE: To compare two aflibercept treatment regimens and the electrophysiological outcome concerning cone and rod function in age-related macular degeneration (nAMD) over 18 months. METHODS: 41 patients with treatment-naïve nAMD were randomized 1:1 to either arm 1 or 2. Arm 1 received three conse...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033741/

データ提供：米国国立医学図書館（NLM）

Aflibercept for Neovascular Age-Related Macular Degeneration: Two Regimens Compared

The [treatment of neovascular age-related macular degeneration (nAMD)] is an ever-evolving field, with researchers constantly seeking optimal treatment strategies. This study compares two aflibercept treatment regimens for nAMD over an 18-month period, assessing visual acuity, central retinal thickness, and electrophysiological outcomes.

The study found no significant differences in visual acuity or central retinal thickness between the two regimens, suggesting that both approaches were effective in managing nAMD. However, the study also observed a decline in the combined rod-cone a-wave amplitude and isolated rod b-wave amplitude, potentially indicating potential toxicity to rods or the natural progression of the disease.

Aflibercept: Balancing Efficacy and Potential Risks

The study results highlight the importance of balancing efficacy with potential risks when using aflibercept for nAMD. While both regimens demonstrated positive outcomes in terms of visual acuity and central retinal thickness, the observed changes in rod function warrant further investigation to understand the long-term impact of aflibercept on retinal health.

Navigating nAMD: A Journey of Vigilance

Living with nAMD can feel like navigating a desert, where each step must be carefully considered. This study underscores the importance of ongoing monitoring and understanding the potential risks and benefits of treatment options. Consult with your ophthalmologist to discuss the best approach for managing your nAMD based on your individual needs and circumstances.

Dr.Camel's Conclusion

This study, like a camel caravan traversing a vast desert, delves into the complex terrain of nAMD treatment. It highlights the importance of considering both the immediate benefits and potential long-term impacts of treatment choices. Remember, your eye health is a delicate balance, and seeking guidance from your ophthalmologist is crucial to navigating this journey safely and effectively.

Date :
  1. Date Completed 2022-04-26
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

35218455

DOI: Digital Object Identifier

PMC9033741

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.